Lonza agreed to acquire the Genentech large-scale biologics manufacturing site in Vacaville, California, from Roche for $1.2 billion. The acquisition will increase Lonza’s large-scale biologics manufacturing capacity to meet demand for commercial mammalian contract manufacturing from customers with existing commercial products, plus molecules currently on the path to commercialization within its network. Lonza’s new facility…

CDMO giant Lonza Group (OTCMKTS:LZAGY) has revealed its plans to establish a new lab in Cambridge, Massachusetts. The facility will primarily support small- and medium-sized biotech companies. In particular, the facility will help clients optimize candidates by detecting and resolving potential issues in the early-stages of development before starting clinical trials. This move is part…

Contract development and manufacturing organization Lonza has completed the expansion of its highly potent API (HPAPI) multipurpose suite in Visp, Switzerland. The expansion gives Lonza additional development and manufacturing capacity for antibody-drug conjugates (ADC) payloads. The site includes a range of equipment for manufacturing payload linkers. Divided into cleavable and non-cleavable types, linkers are a vital…

The Swiss multinational manufacturing firm Lonza (SWX:LONN) has bolstered its particle engineering services available at its site in Monteggio, Switzerland. In particular, the new site will offer X-ray powder diffraction (XRPD) services. XRPD is a rapid analytical technique that offers insight into the polymorph and solid-state properties of active pharmaceutical ingredients (APIs). Lonza employees at…

Contract development and manufacturing organization Lonza has announced a series of expansion projects during the pandemic. Most recently, the Basel-based company revealed plans to expand its drug product manufacturing services on its home turf in Switzerland. Included in the expansion will be an installation of a new aseptic fill and finish line in the city…